qCASSCF – a second generation quantum computing technique for drug discovery
to
CR&D Bilateral
Finding new safe and effective medicines is more challenging than ever. A significant shift in the drug development process utilising new methods and technologies is required.
Project partners GTN and Rahko are addressing these problems with disruptive technology, incorporating ideas from quantum physics and machine learning, that will increase the efficiency of the drug development process, decreasing the time and cost it takes to develop new small-molecule drugs.
The goal is to develop and utilise the partners' patented technology platforms to radically improve the likelihood of discovering novel medicines for untreated diseases. This has the potential to re-invigorate work in rare, neglected and hard to treat diseases, impacting a huge number of lives globally.
Get notified when we’re launching.
Want fast, powerful sales prospecting for UK companies? Signup below to find out when we're live.